Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

S. Korea FTC Levies $2.74 Million In Fines On Nine Drug Makers

This article was originally published in PharmAsia News

Executive Summary

South Korea's Fair Trade Commission said it would fine nine pharmaceutical companies operating in the country $2.74 million for allegedly illegal payments to hospitals and physicians for prescribing their drugs

South Korea's Fair Trade Commission said it would fine nine pharmaceutical companies operating in the country $2.74 million for allegedly illegal payments to hospitals and physicians for prescribing their drugs.

The heaviest fines were imposed on Pacific Pharma, HanAllBioPharma and Shin Poong Pharmaceutical. An FTC official said the payments, which the agency calls rebates, are still common in the country. The fines were the result of a law enacted in South Korea last November. (Click here for more)

"FTC Cracks Down On Drug Rebates" - JoongAng Daily (S. Korea) (5/30/11)

Latest Headlines
See All
UsernamePublicRestriction

Register

SC078092

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel